Elearnmarkets - Financial Market Learning
  • Categories
    • Basic Finance
    • Derivatives
    • Financial Planning
    • Fundamental Analysis
    • Technical Analysis
    • Marketshala
    • Miscellaneous
  • Language
    • English
    • Hindi
    • Bengali
No Result
View All Result
  • Courses
  • Webinars
  • Learn On Elearnmarkets
Elearnmarkets - Learn Stock Market, trading, investing for Free
  • Categories
    • Basic Finance
    • Derivatives
    • Financial Planning
    • Fundamental Analysis
    • Technical Analysis
    • Marketshala
    • Miscellaneous
  • Language
    • English
    • Hindi
    • Bengali
No Result
View All Result
  • Courses
  • Webinars
  • Learn On Elearnmarkets
Elearnmarkets - Learn Stock Market, trading, investing for Free
No Result
View All Result
Home Fundamental Analysis
Nifty Pharma

Way Forward for the Pharma Sector

Nifty Pharma Crosses 10,000 – Way Forward For The Pharmaceutical Sector

Elearnmarkets by Elearnmarkets
August 25, 2022
in Fundamental Analysis, Technical Analysis
Reading Time: 5 mins read
0
116
VIEWS
Share on FacebookShare on TwitterShare on WhatsApp

Listen to this:

Donald Trump’s excoriation towards the high pricing of drugs by the pharmaceutical industry anticipated quite a few challenges for the industry.

When he officially became the 45th President of America, these anticipations were converted into a downfall of major pharma stocks.

Read More: Analysis of FII and DII relative to NIFTY price movement

Assumptions were that the industry would be a target to be included in the Border Adjustment Tax that the Republican lawmakers were trying to impose on imports.

For most pharmaceutical manufacturers, more than 40% of their US sales come from exports.

Join TMP Join TMP Join TMP

The downward trend of Nifty Pharma stocks is fully justified as a large portion of the total revenue of the index’s constituent companies is derived from direct exports to the US.

Thus, the expectations of implementation of this import tax made investors wary.

Nifty Pharma Crosses 10,000 – Way Forward For The Pharmaceutical Sector 1
Source: StockEdge

 

Major Reasons of the 3-Year Low of NIFTY Pharma at  8757.8

  1. Compliance hurdles and import reduction were further heightened by deteriorating price environment in the United States.
  2. This was a direct impact of greater competition, triggered when the US Food and Drug Association increased its pace of approvals in America, granting approval to 800 drug applications in 2016, a number known to be the highest for a single year.
  3. The USFDA’s enhanced suspicion towards the Indian pharma companies’ quality control in manufacturing further aggravated their woes. Finding a number of observations in an investigation relating to quality check, the USFDA issued Form 483 to a few Indian pharma majors.
  4. They were also affected by channel consolidation hitting their profit margins. Consolidation i.e. vertical integration of suppliers(medical clinics, pharmacy benefit managers, retail pharmacies) increased the suppliers’ bargaining power with drug manufacturers.

These are the major reasons which resulted in the sector trading at a 3-year low of 8757.8 on May 29, 2017.

Learn technical analysis from scratch by joining:  NSE Academy Certified Technical Analysis course on Elearnmarkets.

Recent slight Increase in Indian Pharma Stocks:

On June 22, 2017, the Business Standard reported a number of patent expiries of drugs.

This seems to be a boon to Indian companies, most being manufacturers of generic drugs.

The opportunity of a sales gain of an equivalent amount exists for generic drugs on account of branded drugs going off-patent.

As of now, the Trump administration is yet to put up an executive order regarding drug costs.

But, a draft order has been put up suggesting an easing of regulations which is contrary to his campaign promises.

The president’s criticism has not been translated into policies impeding the monopoly of the pharma majors, rather the administration has done the exact opposite by rolling back some of the regulations.

As per the draft order, drug companies are expected to get more power to charge higher monopoly prices overseas and give even fewer discounts to hospitals with poor patients resulting in a positive, rather than negative impact on the companies’ profitability.

The existing regulatory and administrative rules cause beneficiaries of Medicare in US to pay the list price, while pharmacy benefit managers (third-party administrators that run the drug plans) get a lower price from drug makers.

The draft order appears to stress on reducing the burden of such regulation.

It is less likely that such regulatory and administrative changes will help in significant reduction of healthcare costs of the citizens.

On account of this draft executive, the woes of the pharmaceutical companies and its investors stand negated and the hope of the stock prices rising is once again instilled.

The Only Fear of Pharma Sector- Value-Based Pricing

Only one policy, known as value-based pricing, if implemented could be detrimental to drug companies, which manufacture very expensive drugs to cure rare diseases.

The idea refers to paying drug companies for the value that a drug brings and refunding money if a drug fails to prevent a critical health condition.

This will benefit drug manufacturers only if their drug is successful in terms of treating a rare disease.

Thus, the companies’ focus will have to shift from expenditure in marketing the drugs to expenditure in research and development.

Yet, there lies Uncertainty…

A certainty about the increase in profitability of the pharma industry cannot be forecasted because of the recent notification by the Indian government regarding prescribing generic names of drugs and the impact of GST( Goods and Service Tax).

In general, for the past few years, Indian government seems to be more inclined towards reducing the burden of healthcare costs on its citizens.

In May 2016, it banned 344 Fixed Drug Combinations (This ban was however lifted by the Delhi High Court, in December) and subsequently, amended the Drug and Cosmetic Rules, 1945.

The amendment made it mandatory for doctors to prescribe generic name two font larger than a trade name.
However, these notifications do not restrict doctors from prescribing branded drug name along with generic name, though it is optional.

The effect of this compulsory prescribing of generic name of drugs has shifted the influencing power from doctors to pharmacists to some extent, while the consumer is the prime beneficiary.

It is obvious that the pharma firms’ promotional budgets will now get more directed towards pharmacists in the form of a volume of discounts as compared to the existing promotions being primarily doctor-centric.
Profit margins of pharmaceuticals are going to diminish because generic drugs with the same constituents as branded drugs are much cheaper than the latter.

The other issue is relating to GST whose implementation has led to unprepared stockists in the supply chain refusing to stock medicines due to the uncertainties of the outcome of this destination-based tax. This issue has been highlighted by Biocon Chairman and Managing Director, Kiran Mazumdar-Shaw herself when she cautioned every one of the possible drug shortage.

As per The Economic Times, dated June 30, 2017, she is said to have claimed that the pharmaceutical companies have taken a huge hit on their margins due to this new taxation policy.

Specific headwinds:

Some particular pharma companies have headwinds of their own.

On June 27, 2017, US FDA announced a new measure which is likely to adversely impact Indian companies like Sun Pharmaceutical, Glenmark Pharmaceuticals, and Dr. Reddy’s Laboratories.

The new regulations involve expediting the review of drug applications where there were fewer than three generics in the market.

The above-mentioned companies face a higher risk because they have a high contribution from drugs with less than three generic approvals and are likely to suffer a major loss of market share due to the increased competition.

In the chart below, it is clear that Sun Pharma has been showing a continuous decline in its Profit After Tax since last year.

Nifty Pharma Crosses 10,000 – Way Forward For The Pharmaceutical Sector 2

 

Source: StockEdge

The Future- Positive, Negative or Uncertain?

The fate of a few specific Indian pharmaceutical majors looks to be uncertain at the moment, given the regulatory headwinds.

However, the overall Indian pharma sector seems to have a brighter future with all the negative anticipations being negated

As time progresses, more clarity will emerge on the policies of the American and the Indian government and we will revisit the landscape to assess the future.

 

 

Tags: english
ShareTweetSend
Previous Post

Nifty Zooms In The Last 30 Minutes And Hits A Fresh Life Time High

Next Post

Nifty Witnesses Minor Profit Booking Post RBI Rate Cut

Elearnmarkets

Elearnmarkets

Elearnmarkets (ELM) is a complete financial market portal where the market experts have taken the onus to spread financial education. ELM constantly experiments with new education methodologies and technologies to make financial education effective, affordable and accessible to all. You can connect with us on Twitter @elearnmarkets.

Related Posts

Technical Analysis in Stock Trading 3
Technical Analysis

Technical Analysis in Stock Trading

May 31, 2023
6.3k
The Ultimate guide to Trading Divergences 4
Technical Analysis

The Ultimate guide to Trading Divergences

May 26, 2023
1k
Trading Psychology: Guide to Master Your Mind in 5 Steps 5
Technical Analysis

Trading Psychology: Guide to Master Your Mind in 5 Steps

May 24, 2023
3.1k
Trading Psychology: 7 Keys to Successful Trading 6
Technical Analysis

Trading Psychology: 7 Keys to Successful Trading

May 22, 2023
3k

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebook-f Twitter Instagram Linkedin-in Youtube Telegram

Register on Elearnmarkets

Continue your financial learning by creating your own account on Elearnmarkets.com

Register Free Account

Download App

Categories

  • Basic Finance
  • Derivatives
  • Financial Planning
  • Fundamental Analysis
  • Technical Analysis
  • Marketshala
  • Miscellaneous

Popular On Elearnmarkets

  • Market Superheroes:
  • Vivek Bajaj
  • Chetan Panchamia
  • Ashish Kyal
  • Premal Parekh
  • Abhijit Paul
  • Jegan
  • Sivakumar Jayachadran
  • Vishal Malkan
  • Jyoti Budhia
  • Vivek Gadodia
  • Vishal Mehta
  • Piyush Chaudhry
  • Santosh Pasi
  • Gomathi Shankar
  • Market Superheroes:
  • Vivek Bajaj
  • Chetan Panchamia
  • Ashish Kyal
  • Premal Parekh
  • Abhijit Paul
  • Jegan
  • Sivakumar Jayachadran
  • Vishal Malkan
  • Jyoti Budhia
  • Vivek Gadodia
  • Vishal Mehta
  • Piyush Chaudhry
  • Santosh Pasi
  • Gomathi Shankar
  • Courses:​
  • Options Trading
  • Dow Theory
  • Momentum Trading
  • Stock Investing
  • Stock Market for Beginners
  • Harmonic Chart Patterns
  • Algo Trading
  • Elliot Wave Theory
  • Advanced Excel
  • Cryptocurrency
  • NSE Certification Course
  • Courses:​
  • Options Trading
  • Dow Theory
  • Momentum Trading
  • Stock Investing
  • Stock Market for Beginners
  • Harmonic Chart Patterns
  • Algo Trading
  • Elliot Wave Theory
  • Advanced Excel
  • Cryptocurrency
  • NSE Certification Course
  • Webinars:
  • Bank Nifty Scalping
  • Intraday Trading Strategies
  • Options Trading Strategies
  • Options selling
  • Price Action
  • Relative Strength
  • Tax Planning
  • Options Buying
  • Growth Stocks
  • Portfolio Management
  • Relative Strength Index
  • Risk Management
  • Renko Charts
  • Crude Oil
  • Traders Psychology
  • Moving Average
  • Multibagger Stocks
  • Webinars:
  • Bank Nifty Scalping
  • Intraday Trading Strategies
  • Options Trading Strategies
  • Options selling
  • Price Action
  • Relative Strength
  • Tax Planning
  • Options Buying
  • Growth Stocks
  • Portfolio Management
  • Relative Strength Index
  • Risk Management
  • Renko Charts
  • Crude Oil
  • Traders Psychology
  • Moving Average
  • Multibagger Stocks
  • Free Learning Modules:
  • Intraday Trading
  • Options Scalping
  • Swing Trading
  • Financial Modelling
  • RSI Indicator
  • Bollinger Bands
  • Pricing of Futures
  • Personal Finance
  • Initial Public Offerings (IPO)
  • Value Investing
  • Technical Indicators
  • Candlesticks
  • Chart Patterns
  • Option Greeks
  • ELSS Funds
  • Banking and Insurance
  • Real Estate
  • Gold
  • Free Learning Modules:
  • Intraday Trading
  • Options Scalping
  • Swing Trading
  • Financial Modelling
  • RSI Indicator
  • Bollinger Bands
  • Pricing of Futures
  • Personal Finance
  • Initial Public Offerings (IPO)
  • Value Investing
  • Technical Indicators
  • Candlesticks
  • Chart Patterns
  • Option Greeks
  • ELSS Funds
  • Banking and Insurance
  • Real Estate
  • Gold
  • Book Summaries:
  • Rich Dad Poor Dad
  • Psychology of Money
  • The Intelligent Investor
  • The Richest Man in Babylon
  • Think and Trade Like a Champion
  • Value Investing and Behavioural Finance
  • Trading in the Zone
  • Learn to Earn
  • Book Summaries:
  • Rich Dad Poor Dad
  • Psychology of Money
  • The Intelligent Investor
  • The Richest Man in Babylon
  • Think and Trade Like a Champion
  • Value Investing and Behavioural Finance
  • Trading in the Zone
  • Learn to Earn
  • Tools:
  • CAGR Calculator
  • SIP Calculator
  • eLearnOptions
  • Future Value Calculator
  • Present Value Calculator
  • Atal Pension Yojana
  • Cost of Delay Calculator
  • Become a Crorepati
  • Tools:
  • CAGR Calculator
  • SIP Calculator
  • eLearnOptions
  • Future Value Calculator
  • Present Value Calculator
  • Atal Pension Yojana
  • Cost of Delay Calculator
  • Become a Crorepati

© 2023 Elearnmarkets. All Rights Reserved

  • Visit Elearnmarkets
  • Courses
  • Webinars
  • Financial Guides
  • Get Free Counselling
  • Visit Elearnmarkets
  • Courses
  • Webinars
  • Financial Guides
  • Get Free Counselling

Get Elearnmarkets App

No Result
View All Result
  • Article Categories
    • Basic Finance
    • Derivatives
    • Financial Planning
    • Fundamental Analysis
    • Technical Analysis
    • Marketshala
    • Miscellaneous
  • Language
    • Hindi
    • Bengali
    • English
  • Courses
  • Webinars

© 2020 Elearnmarkets All Rights Reserved